Navigation Links
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Date:12/1/2008

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need. A Prescription Drug User Fee Act (PDUFA) target date of April 2, 2009 has been established by the FDA for a decision regarding the approval of the Zevalin sBLA. If approved, Zevalin would be the first radioimmunotherapy available to patients as first-line consolidation therapy. It is estimated that there would be approximately 18,000 additional patients that currently receive first-line treatment which would potentially be eligible to use Zevalin under the proposed expanded label.

CTI and Spectrum Pharmaceuticals, Inc. entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, on November 26, 2008 to commercialize and develop ZEVALIN in the United States and expects the transaction will close in early December, 2008. CTI initially acquired the US rights to Zevalin from Biogen Idec in December 2007. CTI gained access to the First-line Indolent Trial (FIT) data through an agreement with Bayer Schering Pharma AG, Germany who used the data to obtain approval for Zevalin as first-line consolidation treatment in Europe.

"We are pleased that the FDA, by granting the application priority review status, acknowledges that the use of Zevalin in the first-line consolidation setting could represent an important treatment option for follicular B-cell non-Hodgkin's lymphoma patients," said James A. Bianco, M.D., CEO of Cell Therapeutic
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
2. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
3. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
4. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
5. FDA Accepts Immucors Response to Warning Letter
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
8. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
9. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
10. FDA Accepts Ranexa(R) sNDA and NDA for Filing
11. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... registered accounting firm, Ernst & Young LLP ("EY") that it ... in a letter delivered to the Company on September 15, ... 16, 2014.  PDL has issued the following ... received a number of inquiries on the reason for the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... Communications , a provider of enterprise networking components, has ... of communications technology. , ,This funding, part of the ... competitive award process. It will enable the company to ... States Army . , ,The request for funding was ...
... I always like about the annual BIO International Conference ... Young always releases at this event its latest report ... Global Biotechnology Industry 2007. , ,This report is chock ... than Ernst & Young covers the global growth of this ...
... from the Public Company Accounting Oversight Board ... within information systems. There are numerous studies, including our ... area. It is worth making the investment to fix ... savings with your Sarbanes-Oxley compliance program. , ...
Cached Biology Technology:The state of global biotech: An Ernst & Young perspective 2The state of global biotech: An Ernst & Young perspective 3The state of global biotech: An Ernst & Young perspective 4The state of global biotech: An Ernst & Young perspective 5The state of global biotech: An Ernst & Young perspective 6Why IT change management is more important than ever 2Why IT change management is more important than ever 3Why IT change management is more important than ever 4
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
(Date:9/17/2014)... team of Spanish researchers have obtained the first partial ... sixteenth century pig found at the site of the ... this ancient pig is closely related to today,s Iberian ... were crossed with modern Iberian pigs. , The study, ... evolutionary aspects of pig species, and particularly on that ...
(Date:9/17/2014)... After decades of decline, grasses have returned to ... eye, the marsh in those places seems healthy again, ... service of the marsh coastal protection remains ... ecosystem function hasn,t come back," said ecologist Mark Bertness, ... the study in the journal Biological Conservation . ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Iberian pig genome remains unchanged after 5 centuries 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... in imaging technology using a combination of light and ... details inside the body. Access to this level of ... but it also has the potential to help health ... symptoms arise. Details describing this advance are published online ...
... Mich. Late-preterm babies those born between 34 and ... and emotional problems, regardless of maternal IQ or demographics, according ... the current edition of the journal Pediatrics . ... have been associated with such problems before, the study represents ...
... more than 60 guides and anglers in the Florida Keys ... assisting in the annual bonefish census. This year,s count, held ... 25-percent from an 8-year mean estimate of 316,805 bonefish to ... Jerry Ault, a fisheries scientist with the University of Miami,s ...
Cached Biology News:Medical imaging breakthrough uses light and sound to see microscopic details inside our bodies 2Late-preterm babies at greater risk for problems later in childhood 2Fall bonefish census sounds warning bell that warrants careful future monitoring 2
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: